WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene today announced the completion of the $150 million Series B funding. NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact ...

Mark Hiatt, MD, MBA, MS, Senior Vice President of Market Access and Strategy, BostonGene Anna Ogloblina, PhD, Senior Director of Market Access and Product Management, BostonGene This session will ...

WALTHAM, Mass., June 09, 2025--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients Designed to Improve Patient Care and Increase Clinical Trial Enrollment WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, ...

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, and Weill Cornell Medicine , today announced a publication ...

BostonGene’s Foundation Model of Cancer and the Immune System–Led Approach Recognized for Advancing Precision Oncology and De-Risking Drug Development for Biopharma BostonGene, developer of the ...

BostonGene to demonstrate its cutting-edge immune system profiling for personalized immunotherapy and real-time clinical decision-making BostonGene, a leading provider of AI-driven molecular and ...

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO Annual Meeting (ASCO), scheduled to take place ...

Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune Biology ...